lung adenocarcinoma
Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients
Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access.
Blood Lipid Mass Spectrometry Assay May Enable Early-Stage Lung Cancer Detection
Researchers in China have come up with a machine learning- and lipidomics-based strategy for detecting lung cancer early in blood samples.
The assay uses a genomic DNA signature called the metastatic potential score derived from copy number alteration analysis of specific regions of the genome.
Use of the Oncomine Focus Assay led to an expansion of genomic profiling for all guideline-recommend alterations and the identification of a broad set of clinically relevant targets.
Computational Approach Shows Promise for Image-Based Lung Cancer Classification
Using deep learning, researchers attempted to classify non-small lung cancer subtypes and predict lung adenocarcinoma mutations from histopathology slides.